Siderophore cephalosporin
Cefiderocol
Brand names: Fetcroja
Adult dose
Dose: 2g IV q8h
Route: IV
Frequency: q8h
Clinical pearls
- NICE TA763 / TA836: limited treatment options for aerobic gram-negative bacilli (CRE, MDR Pseudomonas, Acinetobacter) — restricted to specialist microbiology
- UKHSA AMR strategy
- BSAC stewardship
Contraindications
- Severe beta-lactam hypersensitivity
Side effects
- Diarrhoea
- Hypersensitivity
- C. difficile
- Hepatic enzyme elevation
Interactions
- No major identified
Monitoring
- Renal function
- C. diff
- Microbiological response
Reference: BNF; NICE TA763; BSAC; UKHSA AMR; SmPC; https://bnf.nice.org.uk/drugs/cefiderocol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023